Adverts

Open Access Articles- Top Results for Meptazinol

Meptazinol

</th></tr></th></tr>
Meptazinol
300px
Systematic (IUPAC) name
(RS)-3-(3-ethyl-1-methylazepan-3-yl)phenol
Clinical data
AHFS/Drugs.com International Drug Names
Low
Oral, IM, IV
Pharmacokinetic data
Metabolism The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours.
Half-life Half-Life (1.4–4 hours).
Excretion The drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine.
Identifiers
59263-76-2 7pxN
N02AX05
PubChem CID 41049
ChemSpider 37469 7pxY
UNII 18Y7S5JKZD 7pxY
KEGG D08182 7pxY
ChEMBL CHEMBL314437 7pxY
Chemical data
Formula C15H23NO
233.34922 g/mol
 14pxN (what is this?)  (verify)

Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s.[1] Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth). A partial µ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full µ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.[2]

It does not appear in the US Controlled Substances Act 1970; it may or may not be regulated as an analogue of controlled relatives such as proheptazine (ACSCN 9643)

References

  1. ^ US patent 4197239, Cavalla JF, Shepherd RG, White AC, "Hexahydroazepine, Piperidine and Pyrrolidine Derivatives", issued 1980-04-08, assigned to Wyeth 
  2. ^ Holmes B, Ward A (1985). "Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy". Drugs 30 (4): 285–312. PMID 2998723. doi:10.2165/00003495-198530040-00001. 

External links

Template:Opioidergics


Lua error in package.lua at line 80: module 'Module:Buffer' not found.